Catalyst Calendar

Fri, Sep 4, 2026

1 updates

8:00 AM

Alumis to Participate in Upcoming September Investor Conferences

SOUTH SAN FRANCISCO, Calif., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company will participate in the following investor

alumis.com

Tue, Sep 1, 2026

1 updates

ALMS

7:30 AM

Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)

– LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-high) support moving forward with Phase 3 development in SLE – – Pharmacodynamic data substantiate

Trial Results • Phase 2Topline results Tue, Sep 1, 2026, 8:30 AM EDTalumis.com